FiltersReset Filters

Boxed warnings

With box warnings

Without box warnings

Brand Type

Branded

Generic

57 results

All filters

• alecensa

  (ALECTINIB HYDROCHLORIDE)

  Medication Details

  Genentech, Inc.

  Usage: ALECENSA is indicated for the adjuvant treatment of adults with resected ALK-positive non-small cell lung cancer (NSCLC), and for the treatment of adult patients with metastatic ALK-positive NSCLC, both as detected by an FDA-approved test.

  Medication Details

  Drug Interactions

• alunbrig

  (brigatinib)

  Medication Details

  Takeda Pharmaceuticals America, Inc.

  Usage: ALUNBRIG is indicated for the treatment of adult patients with ALK-positive metastatic non-small cell lung cancer (NSCLC), confirmed by an FDA-approved test.

  Medication Details

  Drug Interactions

• augtyro

  (repotrectinib)

  Medication Details

  E.R. Squibb & Sons, L.L.C.

  Usage: AUGTYRO is indicated for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) and for patients aged 12 and older with NTRK gene fusion-positive solid tumors that are advanced or metastatic, or where surgery poses severe risk, and have limited treatment options.

  Medication Details

  Drug Interactions

• ayvakit

  (avapritinib)

  Medication Details

  Blueprint Medicines Corporation

  Usage: AYVAKIT® is indicated for adults with unresectable or metastatic gastrointestinal stromal tumors (GIST) with PDGFRA exon 18 mutations, advanced systemic mastocytosis (AdvSM), and indolent systemic mastocytosis (ISM). It is not recommended for patients with platelet counts below 50 × 10⁹/L.

  Medication Details

  Drug Interactions

• balversa

  (Erdafitinib)

  Medication Details

  Janssen Products LP

  Usage: BALVERSA is indicated for treating adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with FGFR3 genetic alterations, following progression on at least one prior systemic therapy. Selection of patients must utilize an FDA-approved companion diagnostic. It is not recommended for those eligible for PD-1 or PD-L1 inhibitors.

  Medication Details

  Drug Interactions

• cabometyx

  (cabozantinib)

  Medication Details

  Exelixis, Inc.

  Usage: CABOMETYX is indicated for advanced renal cell carcinoma (RCC), both as a monotherapy and in combination with nivolumab. It is also used for hepatocellular carcinoma (HCC) after sorafenib treatment and for locally advanced or metastatic differentiated thyroid cancer (DTC) in patients 12 and older who are radioactive iodine-refractory.

  Medication Details

  Drug Interactions

• cometriq

  (cabozantinib)

  Medication Details

  Exelixis, Inc.

  Usage: COMETRIQ is indicated for the treatment of patients with progressive, metastatic medullary thyroid cancer (MTC).

  Medication Details

  Drug Interactions

• cosela

  (trilaciclib)

  Medication Details

  G1 Therapeutics, Inc.

  Usage: COSELA is indicated to reduce the incidence of chemotherapy-induced myelosuppression in adults prior to platinum/etoposide or topotecan regimens for extensive-stage small cell lung cancer (ES-SCLC).

  Medication Details

  Drug Interactions

• cotellic

  (COBIMETINIB)

  Medication Details

  Genentech, Inc.

  Usage: COTELLIC® is indicated for adult patients with unresectable or metastatic melanoma harboring BRAF V600E or V600K mutations, in combination with vemurafenib. It is also indicated as a single agent for the treatment of adult patients with histiocytic neoplasms.

  Medication Details

  Drug Interactions

• everolimus

  (Everolimus)

  Medication Details

  ENDO USA, Inc.

  Usage: Everolimus Tablets are indicated for postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer; adults with progressive neuroendocrine tumors (pancreatic, gastrointestinal, or lung origin); advanced renal cell carcinoma after prior treatment failure; renal angiomyolipoma associated with tuberous sclerosis complex; and subependymal giant cell astrocytoma in TSC patients.

  Medication Details

  Drug Interactions